Oncology (all articles) | Page 21 of 124 | Links Medicus Content Curation & Alerts in Medicine

🔥Targeting FGFR2b in gastric & gastro-oesophageal junction adenocarcinoma🔥@TheLancetOncol https://t.co/Rc6AGRIf4a
✅FIGHT: FOLFOX6 + plc. vs bemarituzumab
👉mPFS: 9.5 vs 7.5 mo, n.s.
👉mOS: 19.2 vs 13.5 mo
⛔️eye tox & stomatitis
✅FORTITUDE-101/102 ongoing@myESMO @OncoAlert pic.twitter.com/JTL23o23dY

— Arndt Vogel (@ArndtVogel) October 17, 2022

Single-arm phase 1b study | Chronic convection-enhanced delivery of topotecan for patients with recurrent glioblastoma.

11 Nov, 2022 | 13:00h | UTC

Chronic convection-enhanced delivery of topotecan for patients with recurrent glioblastoma: a first-in-patient, single-centre, single-arm, phase 1b trial – The Lancet Oncology (link to abstract – $ for full-text)

NICE Guideline Update | Colonoscopic surveillance in adults with inflammatory bowel disease or adenomas.

10 Nov, 2022 | 14:16h | UTC

Colorectal cancer prevention: colonoscopic surveillance in adults with ulcerative colitis, Crohn’s disease or adenomas – National Institute for Health and Care Excellence

British Society of Gastroenterology/Association of Coloproctology of Great Britain and Ireland/Public Health England post-polypectomy and post-colorectal cancer resection surveillance guidelines – Gut

Consensus Statement: U.S. Multi-Society Task Force on Colorectal Cancer now suggests average-risk CRC screening begins at age 45.

USPSTF Statement: Start colorectal cancer screening at 45 years for most patients.

ACG Clinical Guidelines: Start colorectal cancer screening at 45

Evidence-based clinical practice guidelines for management of colorectal polyps – Journal of Gastroenterology

Meta-analysis: Risk of colorectal cancer and cancer related mortality after detection of low-risk or high-risk adenomas, compared with no adenoma, at index colonoscopy

Recommendations for Follow-Up After Colonoscopy and Polypectomy: A Consensus Update by the US Multi-Society Task Force on Colorectal Cancer – Gastroenterology

Endoscopic surveillance after surgical or endoscopic resection for colorectal cancer: European Society of Gastrointestinal Endoscopy (ESGE) and European Society of Digestive Oncology (ESDO) Guideline – Endoscopy

Single-arm P2 study | Hypofractionated, 3-week, preoperative radiotherapy for patients with soft tissue sarcomas.

9 Nov, 2022 | 12:24h | UTC

Hypofractionated, 3-week, preoperative radiotherapy for patients with soft tissue sarcomas (HYPORT-STS): a single-centre, open-label, single-arm, phase 2 trial – The Lancet Oncology (link to abstract – $ for full-text)

News Release: Shorter course of radiation therapy yields comparable results for patients with non-metastatic soft tissue sarcoma – The University of Texas MD Anderson Cancer Center

Phase 2 RCT | Concurrent Bevacizumab and reirradiation vs. Bevacizumab alone as treatment for recurrent glioblastoma.

9 Nov, 2022 | 12:21h | UTC

NRG Oncology/RTOG1205: A Randomized Phase II Trial of Concurrent Bevacizumab and Reirradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma – Journal of Clinical Oncology (link to abstract – $ for full-text)

Commentary: Bevacizumab Plus Reirradiation Improves PFS in Glioblastoma Multiforme – OncLive

Review | Direct oral anticoagulants for the prevention and acute treatment of cancer-associated thrombosis.

9 Nov, 2022 | 12:13h | UTC

Direct Oral Anticoagulants for the Prevention and Acute Treatment of Cancer-Associated Thrombosis – Vascular Health and Risk Management

RCT | Comparison of two chemotherapy regimens in patients with newly diagnosed Ewing sarcoma.

9 Nov, 2022 | 12:12h | UTC

Comparison of two chemotherapy regimens in patients with newly diagnosed Ewing sarcoma (EE2012): an open-label, randomised, phase 3 trial – The Lancet (link to abstract – $ for full-text)

Single-arm P2 study | Neoadjuvant relatlimab and nivolumab in resectable melanoma.

8 Nov, 2022 | 12:11h | UTC

Neoadjuvant relatlimab and nivolumab in resectable melanoma – Nature

News Release: Neoadjuvant immunotherapy with relatlimab and nivolumab is safe and effective in stage III melanoma – MD Anderson News Release

Commentary on Twitter

In a phase II trial of neoadjuvant & adjuvant nivolumab+relatlimab in 30 pts with stage III or oligometastatic stage IV melanoma, the pCR rate was 57%, with a 70% pRR; 1- & 2-yr RFS was 100% & 92% vs 88% & 55% for pts with vs without any path. response: https://t.co/2ypNeUTpwb

— NatureRevClinOncol (@NatRevClinOncol) November 1, 2022

SR | Efficacy and safety of stereotactic body radiotherapy for painful bone metastases.

8 Nov, 2022 | 12:00h | UTC

Efficacy and safety of stereotactic body radiotherapy for painful bone metastases: Evidence from randomized controlled trials – Frontiers in Oncology

RCT | Low-dose immunotherapy (nivolumab) may improve outcomes when added to chemotherapy for head and neck cancer.

7 Nov, 2022 | 12:26h | UTC

Low-Dose Immunotherapy in Head and Neck Cancer: A Randomized Study – Journal of Clinical Oncology (link to abstract – $ for full-text)

Commentary from the author on Twitter

Low-Dose Immunotherapy has made immunotherapy more accessible, and has brought down the cost of therapy from 60-80 lakhs to below 5.0 lakhs per year. Hugh cost saving. A step towards atmanirbhar Bharat. @PMOIndia @TOIIndiaNews @ndtv @ZeeNews @the_hindu https://t.co/c0WuC9Wlfk

— Dr (Prof). Vijay Patil (@DrVijayPatil11) October 21, 2022

Post-trial follow-up | Long-term outcomes with stereotactic radiosurgery vs. whole-brain RT for resected brain metastasis.

7 Nov, 2022 | 12:22h | UTC

Association of Long-term Outcomes With Stereotactic Radiosurgery vs Whole-Brain Radiotherapy for Resected Brain Metastasis: A Secondary Analysis of The N107C/CEC.3 (Alliance for Clinical Trials in Oncology/Canadian Cancer Trials Group) Randomized Clinical Trial – JAMA Oncology (link to abstract – $ for full-text)

Commentary: Survivors face less late cognitive deterioration after stereotactic radiosurgery than WBRT – medwire News

Original Study: Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC·3): a multicentre, randomised, controlled, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)

Commentary on Twitter

In pts w limited brain mets after surgical resection, secondary analysis of rand phase 3 trial shows more patients declined significantly in 1 or more cognitive tests with whole brain radiation therapy (WBRT) vs stereotactic radiosurgery (SRS) https://t.co/6nSCO5kSpW #BTSM

— JAMA Oncology (@JAMAOnc) October 22, 2022